The short version of anti-doping fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-09-06 and is reviewed periodically as new material appears.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | SR9009; Stenabolic | Nickname is not a chemical name. |
| Typical analytical method | LC-MS/MS | Often with isotope-labeled internal standard. |
| Storage temperature | -20 °C | Desiccated and protected from light. |
| Solution stability | DMSO stock; avoid freeze-thaw | Store at -20 to -80 °C. |
| Regulatory status | Not approved; varies by country | May be restricted as research chemical. |
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
The hallmark of linear azol(in)e-containing peptide (LAP) biosynthesis is the formation of azol(in)e heterocycles from the nucleophilic amino acids serine, threonine, or cysteine. This is accomplished by three enzymes referred to as the B, C, and D proteins; the precursor peptide is referred to as the A protein, as in other classes. The C protein is mainly involved in leader peptide recognition and binding and is sometimes called a scaffolding protein. The D protein is an ATP-dependent cyclodehydratase that catalyzes the cyclodehydration reaction, resulting in formation of an azoline ring. This occurs by direct activation of the amide backbone carbonyl with ATP, resulting in stoichiometric ATP consumption. The C and D proteins are occasionally present as a single, fused protein, as is the case for trunkamide biosynthesis. The B protein is a flavin mononucleotide (FMN)-dependent dehydrogenase which oxidizes certain azoline rings into azoles. The B protein is typically referred to as the dehydrogenase; the C and D proteins together form the cyclodehydratase, although the D protein alone performs the cyclodehydration reaction. Early work on microcin B17 adopted a different nomenclature for these proteins, but a recent consensus has been adopted by the field as described above.
Ethanol-containing beverages can cause alcohol flush reactions, exacerbations of rhinitis, and, more seriously and commonly, bronchoconstriction in patients with a history of asthma, and in some cases, urticarial skin eruptions, and systemic dermatitis. Such reactions can occur within 1–60 minutes of ethanol ingestion, and may be caused by:
A House of Lords inquiry finds that former speaker Baroness Frances D'Souza broke rules on "personal honour" by writing to Metropolitan Police Commissioner Sir Mark Rowley on Lords headed notepaper to query multiple breaches of the 20 mph speed limit adding up to £400 in fines. 16 October – Liberal Democrat councillors win six council seats at county and borough level in Surrey following a series of by-elections. 17 October – Rupert Lowe, MP for Great Yarmouth and former Reform UK member, is given a seat on the Public Accounts Committee following support from Conservative MPs. 18 October – Conservative MP George Freeman says he has reported a deepfake video depicting him announcing his defection to Reform UK to the police. 19 October – Reform UK's Linden Kemkaran, the leader of Kent County Council, threatens to expose the "cowards" who leaked a video appearing to show her swearing and telling councillors from her party to "suck it up". V-levels are announced by the Department for Education as a new qualification for 16-year-olds. 20 October – Four Reform UK councillors on Kent County Council – Paul Thomas, Oliver Bradshaw, Bill Barret and Maxine Fothergrill – are suspended from the party following leaked video footage of a heated online meeting. Junior minister Claire Hughes reveals she has been diagnosed with breast cancer, and says she will step back from her role while undergoing treatment. Fiona Goddard and Ellie-Ann Reynolds resign from the grooming gang inquiry panel.
CEP-32496 (renamed RXDX-105) a small molecule inhibitor of BRAF, EGFR and RET, now in Phase I/II trials CEP-40783 (renamed RXDX-106) a small molecule inhibitor of AXL and c-Met in preclinical development CEP-40125 (renamed RXDX-107) a nanoformulation of a modified bendamustine with potential activity in solid tumours. Bendamustine Rapid Infusion as therapy for CLL and NHL is part of Teva's specialty drugs pipeline. TEV-44229 (renamed RXDX-108) a potent inhibitor of the kinase PKCiota In July 2019, the company stopped production of Vincristine, a critical drug used to treat the most common forms of childhood cancer, and was criticized by media for creating a worldwide shortage of the drug. On 28 January 2020, the company announced that the Food and Drug Administration (FDA) had approved an autoinjector device for Ajovy (fremanezumab-vfrm) injection.
Sources: en.wikipedia.org
=== Safety === By definition, a first-in-class drug does not have the safety evidence from analogous products that not-first-in-class drugs would have. However, a study investigating recalls and warnings in relation to first-in-class drugs approved between 1997 and 2012 by Health Canada has found that first-in-class drugs actually have a more favourable benefit-to-harm ratio.
Restriction Fragment Length Polymorphism (RFLP) is a technique for analyzing the variable lengths of DNA fragments that result from digesting a DNA sample with a restriction endonuclease. The restriction endonuclease cuts DNA at a specific sequence pattern known as a restriction endonuclease recognition site. The presence or absence of certain recognition sites in a DNA sample generates variable lengths of DNA fragments, which are separated using gel electrophoresis. They are then hybridized with DNA probes that bind to a complementary DNA sequence in the sample. In polymerase chain reaction (PCR) analysis, millions of exact copies of DNA from a biological sample are made. It used to amplify a specific region of a DNA strand (the DNA target). Most PCR methods typically amplify DNA fragments of between 0.1 and 10 kilo base pairs (kb), although some techniques allow amplification of fragments up to 40 kb in size. PCR also uses heat to separate the DNA strands. DNA fragmented during apoptosis, of a size from 1 to 20 nucleosomes, can be selectively isolated from the cells fixed in the denaturing fixative ethanol
== Origin == The first 29 amino acids of GHRH were discovered to be as equally potent as its full 44 amino acid structure This fragment became known as GRF (1-29). However, due to a rapid metabolic clearance analogues of GRF (1-29) were synthesized to enhance the biological activity and reduce the rapidity of metabolic clearance. These analogues were primarily created by substituting amino acids within the peptide structure for amino acids more resistant to enzymatic cleavage. One early analogue substituted the amino acid L-alanine (abbreviated as Ala or A) at the 2nd position of the peptide structure for its optical isomer (mirror image), D-alanine (abbreviated as D-Ala). This substitution resulted in a peptide bond between D-Ala and the 3rd amino acid in the structure aspartic acid (Asp) more able to resist rapid cleavage by the enzyme dipeptidyl peptidase-4, a cleavage which had previously led to an inactive peptide fragment. This successful modification prompted the further creation of analogues with additional amino acid substitutions. In 2005, the first specific mention of tetrasubstituted GRF (1-29) appeared in a study that used it as one of the GRF (1-29) analogue peptide structures studied. The term was used to describe the replacement of the 2nd, 8th, 15th, and 27th amino acids in the structure of GRF (1-29).
The dynamic behavior of Min proteins has been reconstituted in vitro using artificial lipid bilayers, with varying lipid composition and different confinement geometry as mimics for the cell membrane. The first pattern to be reconstituted were spiraling waves of MinD chased by MinE, followed by the reconstitution of waves of all three proteins, MinD, MinE and MinC. Importantly, MinD and MinE can self-organize into a wide variety of patterns depending on the reaction conditions. Additional study is required to elucidate the extent of temporal and spatial signaling permissible by this biological function. These in vitro systems offered unprecedented access to features such as residence times and molecular motility.
February 20: Decrees enacting the Conventions on the night work of women and of children in industry, drawn up in Washington by the International Labor Conference and signed in Paris on January 24, 1921, by France and Belgium, along with their annexed protocol. August 10: Nationality law. December 6: Decree on the regulations of the École nationale supérieure de céramique in Sèvres, reserved for boys. 1928
Sources: en.wikipedia.org
Ed's passing reunites Dan with his estranged half-brother, Ed, Jr. During the final episode of Season 9, which was later retconned out of existence, Roseanne reveals that the entire series was written as a fictional book based on her life and family in which she selectively altered unpleasant events. Most notably, during the final season, Dan and Roseanne are shown as briefly separating after Dan has a short-lived dalliance with another woman while in California, though he had actually died from his heart attack near the end of Season 8. Writing that he was unfaithful was to express her feelings of anger, loss, and abandonment that his death caused. Dan's potential absence from all or most of season nine prompted Phil Rosenthal of the Los Angeles Daily News to describe it as a rare occasion where ending the show would be preferred to doing without. Rosenthal described Goodman's potential absence as leaving a tremendous void, owing to his ability to make those acting with him better. The revelation that Dan actually died and the series' being a work of fiction within the show was not well received. In Season 10, which takes place twenty years after Season 9, Dan is alive, married to Roseanne, and now a grandfather of three. Dan is still a contractor and Roseanne earns money as an Uber driver. They struggle financially while navigating the difficulties of growing older amid exorbitant drug prices and rising medical costs. They are unable to afford Roseanne's knee surgery, leading her to abuse pain-killer drugs.
Pelvifemoral (Leyden-Möbius) LGMD: Weakness is first apparent in the pelvic girdle, and later in the shoulder girdle. Onset is early. It is the most frequent subtype. Scapulohumeral (Erb) LGMD: Weakness is first apparent the shoulder girdle, and later in the pelvic girdle. Onset is later, and symptoms are milder. HyperCKemia: No symptoms, although serum creatine kinase levels are high. There is a less common, autosomal dominant form, which is milder than the autosomal recessive forms, ranging from no symptoms to wheel chair dependence after age 60.
3D Realms was eventually acquired in part by Interceptor Entertainment, and in 2014, Interceptor announced plans to make a new Duke Nukem game, Duke Nukem: Mass Destruction. Gearbox filed suit against 3D Realms and Interceptor based on the fact that Gearbox now owned the rights to the Duke Nukem franchise. The case was settled out of court in August 2015, with 3D Realms and Interceptor acknowledging that Gearbox has full rights to the Duke Nukem series. Following the settlement, Gearbox released Duke Nukem 3D: 20th Anniversary Edition World Tour in September 2016. The game included new levels developed in conjunction with some of the original developers, re-recorded lines by original Duke voice actor Jon St. John, and new music from original composer Lee Jackson. It was released on October 11, 2016.
== External links == "Corticotropin-releasing Factor Receptors: CRF1". IUPHAR Database of Receptors and Ion Channels. International Union of Basic and Clinical Pharmacology. Archived from the original on 2015-11-20. Retrieved 2008-12-04. Corticotropin-releasing+hormone+receptors at the U.S. National Library of Medicine Medical Subject Headings (MeSH) CRF+receptor+type+1 at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Overview of all the structural information available in the PDB for UniProt: P34998 (Corticotropin-releasing factor receptor 1) at the PDBe-KB.
Sources: en.wikipedia.org
The most common approach is liquid chromatography-tandem mass spectrometry, often after extraction from blood, urine, or tissue. Ultraviolet detection and nuclear magnetic resonance spectroscopy are used mainly for reference material characterization. Isotope-labeled internal standards improve accuracy.
Solid material is usually kept at -20 °C, desiccated, and protected from light. Dimethyl sulfoxide stocks should be stored cold and subjected to minimal freeze-thaw cycles. Aqueous solutions are generally less stable and should be prepared fresh when possible.
Legality depends on the country and the intended use. It is not an approved medicine, and some places restrict or ban sales for human consumption. Buyers should verify local rules and product documentation before procurement.
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.